Instil BioTIL
About: Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
Employees: 49
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1.57% more ownership
Funds ownership: 65.43% [Q1] → 67.0% (+1.57%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
2% less capital invested
Capital invested by funds: $45.9M [Q1] → $44.8M (-$1.12M) [Q2]
3% less funds holding
Funds holding: 31 [Q1] → 30 (-1) [Q2]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q1] → 3 (-1) [Q2]
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 26 / 54 met price target | 264%upside $120 | Buy Reiterated | 17 Sept 2024 |
HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 26 / 54 met price target | 264%upside $120 | Buy Maintained | 16 Sept 2024 |
Baird Jack Allen 50% 1-year accuracy 5 / 10 met price target | 445%upside $180 | Outperform Reiterated | 16 Sept 2024 |
Baird Jack Allen 50% 1-year accuracy 5 / 10 met price target | 445%upside $180 | Outperform Maintained | 13 Sept 2024 |
HC Wainwright & Co. Mitchell Kapoor 48% 1-year accuracy 26 / 54 met price target | 21%upside $40 | Buy Maintained | 12 Sept 2024 |